Comparison of the Efficacy of Empagliflozin, Dapagliflozin, and Allopurinol Based on Serum Uric Acid Levels and Kidney Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study
Roland Fejes, Tamás Jámbor, Tamás Lantos, Szabolcs Péter Tallósy · 2025
Read Comparison of the Efficacy of Empagliflozin, Dapagliflozin, and Allopurinol Based on Serum Uric Acid Levels and Kidney Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study by Roland Fejes, Tamás Jámbor, Tamás Lantos, Szabolcs Péter Tallósy (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12821499.txt.
Description
Roland Fejes, Tamás Jámbor, Tamás Lantos, and Szabolcs Péter Tallósy compare three drugs for high uric acid in people with type 2 diabetes. Two are modern diabetes drugs in the SGLT2 class, empagliflozin and dapagliflozin. The third, allopurinol, is the classic gout drug. Kidney health hangs on the choice.
The records study followed over two hundred patients for three years. Both diabetes drugs cut uric acid about as much as allopurinol by the end. They also held kidney filtration steady, while the allopurinol group slid downward year by year. Deaths ran highest in the allopurinol group, though fewest patients quit that drug. The authors favor the newer class for this combined problem.
Catalog record
| CREATOR | Roland Fejes, Tamás Jámbor, Tamás Lantos, Szabolcs Péter Tallósy |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |